Core Viewpoint - Aopu Mai is planning to acquire 100% of Chengli Bio for a combination of cash and stock, raising up to 730 million yuan, despite having significant cash reserves and a low debt ratio. The acquisition has raised concerns due to the presence of a dissenting independent director and discrepancies in valuation among different stakeholders [1][4][15]. Group 1: Acquisition Details - Aopu Mai intends to acquire Chengli Bio for a total valuation of 1.45 billion yuan, with a significant portion of the payment being in shares and cash [5][6]. - The acquisition involves 31 different counterparties, with notable discrepancies in the pricing offered to different stakeholders, leading to a "same stock different price" situation [6][8]. - Chengli Bio's financial performance has been declining, with projected net profit for 2024 expected to drop by 30% compared to the previous year [3][4]. Group 2: Financial Performance - Aopu Mai's revenue for 2023 and 2024 is reported at 243 million yuan and 297 million yuan, respectively, with year-on-year changes of -17.41% and +22.26% [2]. - The net profit for Aopu Mai has significantly decreased, with a drop of 48.72% in 2023 and 61.04% in 2024, leading to concerns about the necessity of the acquisition [2][3]. - Chengli Bio's revenue for 2022, 2023, and 2024 is reported at 256 million yuan, 318 million yuan, and 331 million yuan, respectively, with net profits of 57 million yuan, 65 million yuan, and 45 million yuan [3]. Group 3: Governance and Compliance Issues - An independent director, Tao Hua'an, voted against the acquisition, citing a lack of necessity for the merger at this stage, although specific reasons were not disclosed [4][5]. - Concerns have been raised regarding the relationship between the controlling shareholder of Chengli Bio and the largest stakeholder in the acquiring company, which may affect the compliance and governance of the transaction [10][13][14]. - The valuation discrepancies and the relationships among the stakeholders raise questions about the fairness and transparency of the acquisition process [8][13].

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on June 23, 2025, at 14:00 [1] - The meeting will take place at the company's conference room located at 28, Lane 908, Ziping Road, Pudong New District, Shanghai [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [1][2] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's network voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Specific voting times include trading hours: 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders must complete identity verification to vote online for the first time [5] Agenda Items - The meeting will review several proposals, including the issuance of shares and cash for asset acquisition and related fundraising [3][4] - Proposals include compliance with regulations regarding major asset restructuring and the independence of evaluation agencies [4][9] - The meeting will also address the company's future dividend plans for the years 2025-2027 [9][10] Attendance Requirements - Shareholders must be registered with the China Securities Depository and Clearing Corporation Limited by the close of trading on June 13, 2025, to attend [6] - Registration for attendance must be completed by June 16, 2025, either in person or via email [6][7] Contact Information - For inquiries, shareholders can contact Ma Xiaohan or Chen Hui at 021-20780178 or via email at IR@opmbiosciences.com [8]

Core Points - The company, Shanghai Aopumai Biotechnology Co., Ltd., is planning to acquire 100% equity of Pengli Biological Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, which constitutes a significant asset restructuring [1][2][3] - The total transaction price for the acquisition is approximately RMB 1,450.5 million, with 51.05% paid through share issuance and 48.95% through cash [7] - The financial statements for the years 2023 and 2024 are prepared based on the assumption that the acquisition was completed on January 1, 2023, reflecting the financial position and operating results post-acquisition [3][4][5] Company Overview - Shanghai Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and is headquartered in Shanghai, with a registered capital of RMB 114.77246 million [1][2] - The company primarily engages in technology services, chemical product sales, and research and development of biochemicals and bio-based materials [1][2] Transaction Details - The acquisition involves multiple investors, totaling 31 parties, and does not constitute a related party transaction [2][3] - Pengli Biological, founded in March 2008, focuses on the research and development of new drugs and biopharmaceutical technologies for various diseases [3][4] Financial Reporting - The financial statements are prepared in accordance with the relevant accounting standards and reflect the company's financial condition and operating results for the specified periods [6][8] - The financial statements include a consolidated balance sheet and income statement, with specific notes detailing significant accounting policies and estimates [6][8]

Group 1 - The company plans to acquire 100% equity of Pengli Bio by issuing shares and paying cash, while also raising supporting funds from no more than 35 specific investors [1][2] - The stock of the company will be suspended from trading starting January 17, 2025, due to the uncertainties surrounding the transaction, and will continue to be suspended until January 24, 2025 [2][3] - The board of directors has approved the proposal for the acquisition and fundraising, with relevant documents published on the Shanghai Stock Exchange website [3] Group 2 - The transaction is subject to several conditions, including approval from the shareholders' meeting, review by the Shanghai Stock Exchange, and consent from the China Securities Regulatory Commission [4]

Core Viewpoint - Shanghai Aopumai Biotechnology Co., Ltd. plans to acquire 100% equity of Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, which constitutes a significant asset restructuring [3][4]. Group 1: Transaction Details - The transaction involves the purchase of 100% equity of Pengli Biopharmaceutical, with the company intending to issue shares to no more than 35 specific investors to raise matching funds [3][4]. - The total assets, net assets, and operating income of the acquired assets exceed 50% of the corresponding indicators of the listed company, confirming that this transaction qualifies as a significant asset restructuring [4]. Group 2: Regulatory Compliance - The transaction requires approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission before implementation [4]. - The transaction does not constitute a related party transaction, as there are no existing relationships between the transaction parties and the listed company or its affiliates prior to the transaction [4]. Group 3: Control and Ownership - The controlling shareholder and actual controllers of the company have not changed in the last 36 months, indicating that the transaction does not constitute a restructuring listing [4].

Core Viewpoint - Shanghai Aopumai Biotechnology Co., Ltd. plans to acquire 100% equity of Pengli Biomedical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds from no more than 35 specific investors [1][2]. Group 1 - The company intends to purchase the equity from various investment partners and individuals, including PharmaLegacy Hong Kong Limited and several limited partnership investment firms [1]. - The board of directors has confirmed that the company does not fall under any prohibitive conditions outlined in Article 11 of the "Administrative Measures for the Registration of Securities Issuance by Listed Companies" [2]. - The company has conducted a thorough review and determined that there are no recent negative audit opinions or significant legal issues that would prevent the issuance of shares to specific investors [2].

证券代码：688293 证券简称：奥浦迈 公告编号：2025-050 上海奥浦迈生物科技股份有限公司 关于因实施本次重大资产重组导致控股股东、实际控 制人及持股 5%以上股东权益被动稀释的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司拟通过发行股份及支付现金方式购买 PharmaLegacy Hong Kong Limited、 嘉兴汇拓企业管理合伙企业（有限合伙）、红杉恒辰（厦门）股权投资合伙企业 （有限合伙）、上海景数创业投资中心（有限合伙）、宁波梅山保税港区谷笙澎立 投资合伙企业（有限合伙）、TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有 限合伙）、杭州泰格股权投资合伙企业（有限合伙）、南通东证富象股权投资中心 （有限合伙）、江西济麟鑫盛企业管理有限公司、中金启辰贰期（苏州）新兴产 业股权投资基金合伙企业（有限合伙）、嘉兴合拓企业管理合伙企业（有限合伙）、 苏州晨岭投资合伙企业（有限合伙）、德州两仪幂方康健创业投资合伙企业（有 限合伙）、平阳国凯股权投资合伙企业（有限合伙） ...

Core Viewpoint - Shanghai Aopumai Biotechnology Co., Ltd. plans to acquire 100% equity of Pengli Biotechnology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, involving multiple investment partners [1][3]. Group 1: Acquisition Details - The acquisition involves multiple investment entities, including PharmaLegacy Hong Kong Limited and several limited partnerships, indicating a broad consortium of investors [1]. - The company intends to raise supporting funds by issuing shares to no more than 35 specific investors as part of this transaction [3]. Group 2: Regulatory Compliance - The transaction is in accordance with the "Major Asset Restructuring Management Measures" which stipulates that continuous purchases or sales of the same or related assets within twelve months must be cumulatively calculated [3][4]. - The assets involved in the transaction are recognized as belonging to the same or similar business scope, thus requiring inclusion in the cumulative calculation for this transaction [5]. Group 3: Financial Adjustments - The company has adjusted its capital increase plan for its subsidiary, increasing the planned investment from 20 million RMB to 5 million RMB, reflecting a strategic shift in resource allocation [4]. - The company has also made additional investments in other subsidiaries, such as a 42 million RMB increase in Suzhou Haixing Biotechnology Co., Ltd., acquiring a 30.0014% stake [4][5].

，与本次发行股份及支付现金购买资产合称"本 次交易" ）。 公司聘请了上海东洲资产评估有限公司（以下简称"东洲评估" "评估机构"） 上海奥浦迈生物科技股份有限公司 董事会关于评估机构的独立性、评估假设前提的合 理性、评估方法与评估目的的相关性以及评估定价 的公允性的说明 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"上市公司"）拟 通过发行股份及支付现金方式购买 PharmaLegacy Hong Kong Limited、嘉兴汇拓企 业管理合伙企业（有限合伙） 、红杉恒辰（厦门）股权投资合伙企业（有限合伙） 、 上海景数创业投资中心（有限合伙） 、宁波梅山保税港区谷笙澎立投资合伙企业（有 、TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有限合伙） 限合伙） 、杭州泰格股 权投资合伙企业（有限合伙） 、南通东证富象股权投资中心（有限合伙） 、江西济麟 鑫盛企业管理有限公司、中金启辰贰期（苏州）新兴产业股权投资基金合伙企业（有 限合伙） 、嘉兴合拓企业管理合伙企业（有限合伙） 、苏州晨岭投资合伙企业（有限 合伙） 、德州两仪幂方康健创业投资合伙企业（有限合伙） 、平阳国凯股权投资合伙 企业（有限合 ...

上海奥浦迈生物科技股份有限公司 董事会关于本次交易采取的保密措施及保密制度的 说明 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"上市公司"）拟 通过发行股份及支付现金方式购买 PharmaLegacy Hong Kong Limited、嘉兴汇拓企 业管理合伙企业（有限合伙） 鑫盛企业管理有限公司、中金启辰贰期（苏州）新兴产业股权投资基金合伙企业（有 限合伙） 、嘉兴合拓企业管理合伙企业（有限合伙） 、苏州晨岭投资合伙企业（有限 合伙） 、红杉恒辰（厦门）股权投资合伙企业（有限合伙） 、 上海景数创业投资中心（有限合伙） 、宁波梅山保税港区谷笙澎立投资合伙企业（有 、TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有限合伙） 限合伙） 、杭州泰格股 权投资合伙企业（有限合伙） 、南通东证富象股权投资中心（有限合伙） 、江西济麟 、德州两仪幂方康健创业投资合伙企业（有限合伙） 、平阳国凯股权投资合伙 企业（有限合伙） 、苏州一元幂方医药创业投资合伙企业（有限合伙） 、武汉泰明创 业投资合伙企业（有限合伙） 、上海敬笃企业管理合伙企业（有限合伙） 、王国安、 上海陂季玟企业管理合伙企业（有限合伙） 、 ...